Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients
To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving continuous therapy with cyclosporine (CsA, Sandimmune, Neoral) and sirolimus versus induction with CsA and sirolimus followed by CsA elimination and concentration-controlled sirolimus.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||A Randomized, Open-Label Study of Continuous Therapy With Cyclosporine and Sirolimus Versus Induction With Cyclosporine and Sirolimus Followed by Continuous Therapy With Sirolimus in Renal Allograft Recipients|
- Equivalence of graft survival at month 12
- Renal function; biopsy-confirmed acute rejection, grade of acute rejection; subject and graft survival; incidence of infection, malignancy, treatment failure, and of chronic rejection as determined by protocol biopsies; quality of life.
|Study Start Date:||May 1998|
|Estimated Study Completion Date:||June 2004|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00428064
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|